应用超声单模态融合成像技术指导微波消融治疗原发性肝癌即时疗效评价的价值研究*

doi:10.3969/j.issn.1672-5069.2020.04.030

摘要/Abstract

摘要： 目的研究超声单模态融合成像技术在微波消融治疗原发性肝癌(PLC)患者中的应用价值。方法 2018年3月～2019年12月我院诊治的88例PLC患者,其中44例采用超声单模态融合成像(观察组),另44例采用CT/MRI多模态融合成像(对照组)指导微波消融治疗。结果观察组配准评估时间为(3.8±1.3)min,显著短于对照组【(5.2±1.7)min, P<0.05】,观察组和对照组融合成像成功率分别为63.6%和56.8%,无显著性差异(P>0.05);在44例观察组发现52个病灶,单模态融合成功36个病灶(69.2%),在44例对照组发现54个病灶,多模态融合成功32个病灶(59.3%),两组病灶融合成功率比较,无显著性差异(P>0.05);两组肿瘤完全消融率分别为97.7%和93.2%,无显著性差异(P>0.05);观察组消融治疗后发热、局部疼痛、胆道出血和胆漏并发症发生率分别为9.1%、20.5%、4.5%和0.0%,与对照组的13.6%、27.3%、9.1%和2.3%比,差异无统计学意义(P>0.05);随访3～20个月,观察组生存32例(72.7%),总体生存(OS)为15.1(5.0,20.0)个月,无进展生存(PFS)为12.8(4.9,20.0)个月,对照组生存32例(72.7%),OS为14.2(4.8,20.0)个月,PFS为13.3(4.7,20.2)个月(Log rank x²=0.592, P=0.442;x²=1.103,P=0.294)。结论超声单模态融合成像与CT/MRI多模态融合成像均可用于指导微波消融治疗PLC患者,但超声单模态融合成像更为简便,经济,可提供即时影像学资料,为后续治疗提供依据。

关键词: 原发性肝癌, 微波消融, 超声单模态融合成像, CT/MRI多模态融合成像, 疗效评价

Abstract: Objective The aim of this study was to investigate the application of ultrasound single mode fusion imaging (USMFI) in the immediate evaluation of microwave ablation (MWA) in treatment of patients with primary liver cancer (PLC). Methods The clinical data of 88 patients with PLC were recruited in our hospital from March 2018 through December 2019, and all underwent MWA treatment. During MWA procedures, the USMFI guidance was performed in 44 patients, and CT/MRI multimodal fusion imaging was performed in other 44 patients.Results The registration time in US-guided group was (3.8±1.3) minutes, statistically significantly shorter than (5.2±1.7) minutes in CT/MIR-guided group (P<0.05), and the success rates of fusion imaging were 63.6% vs. 56.8%, not significantly different(P>0.05); 52 foci out of 44 patients in US-guided group were found and the successful fusion imaging was obtained in 36 foci(69.2%), and 54 out 44 patients in CT/MRI-guided group were found and the successful fusion was got in 32 foci (59.3%,P>0.05); the complete ablation rates were 97.7% and 93.2% in the two groups(P>0.05) and the incidences of compliattions such as fever, local pain, bile duct bleeding and bile leakage were 9.1%, 20.5%, 4.5% and 0.0% vs. 13.6%, 27.3%, 9.1% and 2.3%, respectively(P>0.05) in the two groups; at the end of 3 to 20 month followed-up, 32 (72.7%) patients in US-guided group survived with total survival (OS) of 15.1(5.0, 20.0) months and with progress free survival (PFS) of 12.8(4.9, 20.0)months, and 32 (72.7%) patients in CT/MRI-guided group survived with OS of 14.2(4.8, 20.0) months, and PFS of 13.3(4.7, 20.2) months (Log rank x²=0.592, P=0.442; x²=1.103, P=0.294). Conclusion Both the single-mode ultrasound fusion imaging and CT/MRI multi-mode fusion imaging could be applied to guide the MWA in the treatment of patients with PLC, but the former is relatively simple and cheap, and should be chosen first.

Key words: Hepatoma, Microwave ablation, Uultrasound single-mode fusion imaging, CT/MRI multi-mode fusion imaging, Efficacy evaluation

孟海生, 胡冬梅, 王海涛, 顾金凤, 赵静, 梁啸寒. 应用超声单模态融合成像技术指导微波消融治疗原发性肝癌即时疗效评价的价值研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 572-575.

Meng Haisheng, Hu Dongmei, Wang Haitao, et al. Application of ultrasound single mode fusion imaging in the immediate evaluation of microwave ablation in treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2020, 23(4): 572-575.

参考文献

[1]中国抗癌协会原发性肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会原发性肝癌学组. 原发性肝癌局部消融治疗规范的专家共识.中华肝脏病杂志,2011,19(4):257-259.
[2]Salami S S. Prostatecancer diagnosis on repeat magnetic resonance imaging-transrectal ultrasound fusion biopsy of benign lesions: recommendations for repeat sampling.J Urol, 2016, 196(1):67-67.
[3]Bolten K , Fischer TY, Bender YN, et al. Pilot study of MRI/ultrasound fusion imaging, in postpartum assessment of Cesarean section scar. Ultrasound Obst Gyn,2017, 50(4):520-526.
[4]Park S , Jang J , Kim J , et al. Real-timetriple-modal photoacoustic, ultrasound, and magnetic resonance fusion imaging of humans. Ieee T Med Imaging, 2017, 36(9):1912-1921.
[5]Hiraoka A , Hirooka M , Koizumi Y , et al. M2066novel technique for determining therapeutic response to radiofrequency ablation therapy for hepatocellular carcinoma using US-volume system.Gastroenterology,2009, 136(5):A-478.
[6]中国抗癌协会原发性肝癌专业委员会.原发性肝癌规范化病理诊断指南(2015年版).中华肝胆外科杂志,2015,21(3):865-872.
[7]龙颖琳,李凯,郑荣琴,等.超声单模态融合成像技术在肝肿瘤热消融术中即时疗效评估中的初步应用.中华超声影像学杂志,2017,26(4):306-310.
[8]Sebek J , Albin N , Bortel R , et al. Sensitivity of microwave ablation models to tissue biophysical properties: A first step toward probabilistic modeling and treatment planning. Med Phys, 2016, 43(5):2649-2661.
[9]Zhou Q , Wu S , Gong N , et al. Liposomes loading sodium chloride as effective thermo-seeds for microwave ablation of hepatocellular carcinoma.Nanoscale,2017,9(31):11068-11076.
[10]黄仕颖, 梁爽, 魏杨辉,等.CAO方案化疗联合高频聚焦超声消融治疗Ⅲ/Ⅳ期肝母细胞瘤患儿疗效分析.实用肝脏病杂志, 2019,22(4):569-572.
[11]Owjimehr M , Danyali H , Helfroush M S , et al. Staging offatty liver diseases based on hierarchical classification and feature fusion for back-scan-converted ultrasound images. Ultrasonic Imaging, 2016, 39(2):79-95.
[12]Lee S H , Jin Y J , Lee J W . Survival benefit of radiofrequency ablation for solitary (3–5 cm) hepatocellular carcinoma: An analysis for nationwide cancer registry. Medicine, 2017, 96(44):e8486-e8489.
[13]张曼, 李凯, 苏中振,等.融合成像技术辅助普通超声显示困难的肝恶性肿瘤射频消融的应用价值.中华超声影像学杂志, 2016, 25(8):691-695.
[14]Morine Y , Enkhbold C , Imura S , et al. Accurate estimation of functional liver volume using Gd-EOB-DTPA MRI compared to MDCT/99mTc-SPECT fusion imaging. AnticancerRes, 2017, 37(10):5693-5700.
[15]Afshar-Oromieh A , Vollnberg B , Alberts I , et al. Comparison of PSMA-ligand PET/CT and multiparametric MRI for the detection of recurrent prostate cancer in the pelvis. Eur J Nucl Med Mol I, 2019, 46(11):1-9.
[16]Bo X W , Xu H X , Guo L H , et al. Ablative safety margin depicted by fusion imaging with post-treatment contrast-enhanced ultrasound and pretreatment CECT/CEMRI after radiofrequency ablation for liver cancers. Brit J Radiol,2017, 90(1078):63-69.
[17]Okabayashi T , Shima Y , Morita S , et al. Liverfunction assessment using technetium-⁹⁹m-galactosyl single photon emission CT/CT fusion imaging: A prospective trial.J Am Coll Surg, 2017, 225(6):789-795.
[18]Schnabel J A, Heinrich M P, Bartłomiej W, et al. Advances and challenges in deformable image registration: from image fusion to complex motion modelling. Med Image Anal,2016, 33(21):145-148.
[19]Ahn S J , Lee J M , Lee D H , et al. Real-time US-CT/MRfusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma.J Hepatol, 2016, 66(2):347-354.
[20]Li M , Ballhausen H , Hegemann N S , et al. Comparison of prostate positioning guided by three-dimensional transperineal ultrasound and cone beam CT. Strahlen Ther Onkol, 2016, 193(3):221-228.
[21]Wu T , Cao Y , Ni S , et al. Morphometricanalysis of rat spinal cord angioarchitecture by phase contrast radiography: from 2D to 3D visualization. Spine, 2017, 43(9):504-511.

应用超声单模态融合成像技术指导微波消融治疗原发性肝癌即时疗效评价的价值研究^*

Application of ultrasound single mode fusion imaging in the immediate evaluation of microwave ablation in treatment of patients with primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	全亚宁, 商晓杰, 孟璇, 高榆秀. 实时超声造影和融合影像导航下微波消融与手术治疗小肝癌患者疗效比较^*[J]. 实用肝脏病杂志, 2020, 23(4): 581-584.
[2]	魏倩, 王艳, 游岚岚, 苟博. 超声引导下微波消融治疗早期泡型肝包虫病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2020, 23(4): 593-596.
[3]	吴杰,谢丽响,修金. 影像学检查评估TACE治疗的原发性肝癌患者术后残余肿瘤活性价值研究[J]. 实用肝脏病杂志, 2020, 23(3): 419-422.
[4]	王玮, 杜晓菲, 路运健. 术前NLR水平对TACE联合MWA治疗的巨块型原发性肝癌患者生存时间的影响^*[J]. 实用肝脏病杂志, 2020, 23(2): 260-263.
[5]	李颖, 黄海清, 薛富善, 池萍, 李丽. 瑞芬太尼复合丙泊酚靶控输注麻醉用于肝部分切除术患者临床效果研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 272-275.
[6]	李陆鹏, 曹广劭, 曹会存, 刘建文, 刘玉岩. 动脉栓塞术与微波消融术治疗肝海绵状血管瘤患者临床疗效对比研究^*[J]. 实用肝脏病杂志, 2020, 23(2): 276-279.
[7]	陈亮, 段海峰, 余红星. SMI、CDFI和增强CT检查TACE术治疗的原发性肝癌患者癌组织血供显像效果比较^*[J]. 实用肝脏病杂志, 2020, 23(1): 90-93.
[8]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[9]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[10]	黎秋曦, 贾健锋, 黄锐. 经皮微波消融术治疗的肝海绵状血管瘤患者血红蛋白尿发生及其处理*[J]. 实用肝脏病杂志, 2019, 22(5): 732-735.
[11]	崔发强, 李涛, 王铮, 陈青. 原发性肝癌患者外周血KRAS基因水平及其对西妥昔单克隆抗体治疗疗效的影响[J]. 实用肝脏病杂志, 2019, 22(4): 565-568.
[12]	赵晓光, 史玉洁. 应用还原型谷胱甘肽预防处理接受TACE治疗的中晚期原发性肝癌患者对肝功能的影响[J]. 实用肝脏病杂志, 2019, 22(3): 425-428.
[13]	李克田,沈明格,王凤荣,胡春荣,曹玉杰,芦鹏. 血糖水平对原发性肝癌患者¹⁸F-FDG摄取和PET/CT检查图像质量的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 256-259.
[14]	王秀清,马艳君,詹晋莉. 肝动脉化疗栓塞术联合超声引导下微波消融术治疗特殊部位原发性肝癌患者疗效及安全性分析 ^*[J]. 实用肝脏病杂志, 2019, 22(2): 260-263.
[15]	王翠晓, 高静. 血清高尔基蛋白73、甲胎蛋白异质体3、甲胎蛋白和α-L-岩藻糖苷酶水平诊断原发性肝癌的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(1): 113-116.